A Long-Term Study to Assess the Ongoing Safety and Efficacy of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2017
At a glance
- Drugs Olipudase alfa (Primary)
- Indications Niemann-Pick disease type B
- Focus Adverse reactions
- Sponsors Sanofi; Sanofi Genzyme
- 03 Mar 2017 Planned End Date changed from 1 Aug 2021 to 1 Oct 2021.
- 03 Mar 2017 Planned primary completion date changed from 1 Aug 2021 to 1 Oct 2021.
- 04 May 2016 Minimum age of subjects is changed fro 18 years to 1 year